# Filing Detail

Form DEF 14A - Other definitive proxy statements:
SEC Accession No. 0001610618-21-000037
Filing Date
2021-04-28
Accepted
2021-04-28 16:07:15
Documents
4
Period of Report
2021-06-23

Document Format Files

Seq | Description | Document | Type | Size
--- | --- | --- | --- | ---
1 | DEFINITIVE PROXY STATEMENT | cdtxdef14a2021.htm | DEF 14A | 510813
2 |  | cdtx_proxycardxpg011a.jpg | GRAPHIC | 1466917
3 |  | cdtx_proxycardxpg021a.jpg | GRAPHIC | 1131416
4 |  | cdtxlogoa131a.jpg | GRAPHIC | 46741
| Complete submission text file | 0001610618-21-000037.txt |  | 4145602

Mailing Address 6310 NANCY RIDGE DRIVE SUITE 101 SAN DIEGO CA 92121
Business Address 6310 NANCY RIDGE DRIVE SUITE 101 SAN DIEGO CA 92121 858-752-6170
Cidara Therapeutics, Inc. (Filer) CIK: 0001610618 (see all company filings)

EIN.: 461537286 | State of Incorp.: DE | Fiscal Year End: 1231
Type: DEF 14A | Act: 34 | File No.: 001-36912 | Film No.: 21864256
SIC: 2836 Biological Products, (No Diagnostic Substances)